Newsroom
January 4, 2023
Researchers at the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases are researching early indicators of diseases to either prevent or delay the onset of severe symptoms.
December 22, 2022
Gabriel De Erausquin, MD, PhD, MSc, Neurology and the Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, was quoted in this story. Read More
December 15, 2022
American Federation for Aging Research grant allows exploration of signaling molecules toxic in Alzheimer’s, diabetes, aging The American Federation for Aging Research (AFAR) selected Juan Pablo Palavicini, PhD, an early career scientist at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), to receive the 2022 Glenn Foundation for Medical […]
December 8, 2022
The AHEAD clinical trial will assess whether the new Alzheimer’s drug, lecanemab, can delay the onset of dementia in persons who are at high risk of developing the disease. The Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, part of The University of Texas Health Science Center at San Antonio (UT Health San Antonio), […]
December 1, 2022
The AHEAD clinical trial will assess whether the new Alzheimer’s drug, lecanemab, can delay the onset of dementia in persons who are at high risk of developing the disease. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Dec. 1, 2022) — The Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, part of The University of Texas […]
October 27, 2022
In this new season, host Kitty Eisele will explore the importance of how caregivers for loved ones with dementia are portrayed in popular culture.
